Novacyt S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lyn Dafydd Rees
- Full Time Employees
- 234
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 13 Avenue Morane Saulnier Le Vésinet IF France 78140
- IPO Date
- Jan 8, 2021
- Website
- novacyt.com
- Similar Companies
- Business
- Novacyt S.A. (NVYTF) is an international molecular diagnostics company that develops, manufactures and commercialises molecular assays, workflows and instrumentation for clinical, research and instrumentation applications across human health, animal health and environmental sectors; its clinical portfolio targets reproductive health with non-invasive prenatal testing (NIPT), cystic fibrosis and rapid aneuploidy assays, precision medicine including DPYD genotyping, and infectious diseases such as the Winterplex multiplex respiratory PCR panel; the instrumentation segment features Ranger Technology for automated DNA sample preparation and target enrichment, alongside genesig q16 and q32 real-time qPCR instruments; research use only offerings encompass high-performance qPCR assays for human health, agriculture, veterinary and environmental applications, plus pharmaceutical services like whole genome and exome sequencing. The company operates through brands including Primerdesign, founded in 2005 and specialising in real-time PCR kits and reagents supplied to customers in over 100 countries, and Yourgene Health, providing NIPT NGS workflows, PCR assays and Ranger platforms for applications in NIPT, liquid biopsy, oncology and gene synthesis. Headquartered in Le Vésinet, France, with key facilities in Manchester, UK, and offices in Singapore, the US and Canada, Novacyt maintains a commercial presence in over 65 countries and lists on the London Stock Exchange AIM (NCYT) and Euronext Growth Paris (ALNOV). In recent developments, the company completed integration of its 2023 Yourgene Health acquisition ahead of schedule, delivering £5.0 million in cost synergies within 18 months and achieving £3.0 million in additional annual EBITDA improvements from site consolidations including the closure of IT-IS International, relocation of Canadian and Primerdesign manufacturing to Manchester by early 2025; it disposed of its Taiwanese laboratory business, reclaimed £12.2 million in VAT post-DHSC settlement, received EU IVDR accreditation for key assays like Yourgene QST*R Base and Cystic Fibrosis Base, launched norovirus detection for oysters and mpox clade assays, expanded veterinary multiplex panels, supported new NIPT labs in Colombia and Kazakhstan, and plans four 2025 product launches in reproductive health, precision medicine and Ranger Technology backed by £2.0 million extra R&D investment; board changes included appointing Lyn Rees as CEO, Steve Gibson as CFO, Dr Jo Mason as CSO, Dr John Brown as Chairman and Dr Ian Gilham as non-executive director.
Novacyt S.A. (NVYTF) Shareholder/Analyst Call Prepared Remarks Transcript
Novacyt S.A. (NVYTF) Q4 2025 Earnings Call Transcript
Novacyt S.A. (NVYTF) Discusses Acquisition of Southern Cross Diagnostics and Strategic Rationale Prepared Remarks Transcript
Novacyt S.A. (NVYTF) Discusses Interim Results, Growth Strategy, and New Product Introduction Prepared Remarks Transcript
Novacyt S.A. (NVYTF) Q4 2024 Earnings Call Transcript
Novacyt S.A. (NVYTF) Q2 2024 Earnings Call Transcript
Novacyt shares drop 16% on legal settlement news
Novacyt S.A. (NVYTF) Q4 2023 Earnings Call Transcript
Novacyt S.A. (NVYTF) Q2 2023 Earnings Call Transcript
Yourgene jumps 143% on Novacyt £16.7m knock-out bid
Novacyt S.A. (NVYTF) Q4 2022 Earnings Call Transcript
Novacyt gets UK approval for seventh Covid test
Novacyt slips as CEO departs
Novacyt gains UK approval for its multiplex PCR test for detection of winter viruses
Novacyt S.A. (NVYTF) Q2 2022 Earnings Call Transcript
Novacyt receives EU approval for saliva-based Covid test
Novacyt shares slide as DHSC issues a claim against the company
Novacyt has third Covid test approved in UK
Novacyt says COVID-19 test wins UK approval, pares back revenue shortfall guidance
Novacyt pares back revenue shortfall guidance after its COVID-19 test wins CTDA approval in UK